Aetiology of Obstructive Jaundice in Ghana: A Retrospective Analysis in a Tertiary Hospital

Abstract

Background: Obstructive jaundice is a term that describes the clinical entity of yellowness of the skin and mucous membranes due to the inability of bile to flow freely into the duodenum. This is commonly due to mechanical or physiological blockage of either the intrahepatic or extrahepatic bile ducts. Malignancies are responsible for the most cases of obstructive jaundice in our locality. Aim: The study sought to analyse all cases of obstructive jaundice that presented to a tertiary referral centre over a 36-month period, to determine the age at presentation, sex distribution, and aetiological spectrum. Study Design: Retrospective cross-sectional study. Study Setting: Korle-Bu Teaching Hospital, Accra, Ghana. Materials and Methods: This was a hospital-based study of all cases of obstructive jaundice that were seen over a 36-month period from May 2017 to April 2020, at the Hepatobiliary Unit of the Korle-Bu Teaching Hospital. The unit serves as a referral centre for all liver, pancreas, and biliary tract cases, including cases presenting with obstructive jaundice. The demographic data and diagnosis of all cases of obstructive jaundice seen over the study period were retrieved from both out-patient and in-patient records. Results: Three hundred and sixty cases of obstructive jaundice were studied; 141 (39.2%) were males and 219 (60.8%) were females, giving a male-to-female ratio of 1.1.6. The mean age of the patients was 56.8 (SD, 15.9) years. Malignant conditions accounted for 314 (87.2%) cases, whilst 46 (12.8%) were due to benign conditions. The mean age of the patients with benign conditions (40.4 [SD, 15.7] years) was significantly lower than that of those with malignant conditions (59.4 [SD, 14.9] years) (P < 0.0001). There was no significant difference in sex ratios between patients with malignant and benign causes (P = 0.996). Pancreatic head cancer was the commonest malignant cause of obstructive jaundice accounting for 139 (38.61%), followed by gallbladder tumour, 81 (22.5%), whilst choledocholithiasis (23 [6.39%]) was the commonest benign cause of obstructive jaundice. Conclusion: Obstructive jaundice in our setting was more prevalent in females. Malignant aetiologies were more common than benign ones: pancreatic head and gallbladder cancers were the commonest malignancies, whilst choledocholithiasis was the commonest benign cause. Malignant causes occurred in older patients than benign conditions, but there was no difference in sex ratios between the two categories.

Keywords: Aetiological spectrum, biliary tract, gallstone, obstructive jaundice, pancreatic cancer

Introduction

Obstructive jaundice is a term that describes the clinical entity of yellowness of the skin and mucous membranes due to the inability of bile to flow freely into the duodenum. This is usually due to mechanical or physiological causes affecting either the intrahepatic or extrahepatic bile ducts. The blockage leads predominantly to direct hyperbilirubinaemia that accounts for the features of jaundice, dark urine, pruritus, and pale stools.[1] The most common malignant causes of obstructive jaundice are lesions in the head of the pancreas, the gallbladder, or the bile duct, whereas gallstones are the most common benign causes.[2] The diagnosis of pancreatic cancer is often made after the age of 55 years and is therefore defined as a disease of the elderly.[3] Tri-phasic pancreatic-protocol using computer tomography (CT) or magnetic resonance imaging (MRI) scans is adequate for confirming the diagnosis of pancreatic cancer. For resectable pancreatic tumours, surgical resection presents the best curative treatment.[4] Gallbladder cancer is very rare and has a high mortality.[4,5] The asymptomatic nature of the disease and the high tendency to spread to other parts of the body result in a majority of the disease being diagnosed at intermediate to advanced stages for which there are no effective remedies.[6] Gallbladder cancer causes obstructive jaundice through the direct infiltration of the common bile duct (CBD) along the cystic duct or lymph node...
metastasis to the porta hepatis. Diagnosis is confirmed by contrast-enhanced CT scan or MRI. Radical cholecystectomy with adjuvant chemo-radiation offers the best chance of long-term survival.

Cholangiocarcinoma, which is a cancer of the bile duct, is one of the leading causes of obstructive jaundice, with a poor prognosis. Cholangiocarcinoma is a malignant tumour arising from bile duct epithelium that causes partial or complete occlusion of the bile duct. It is the second most common primary liver cancer in the world. 

Cholangiocarcinoma occurs in people over the age of 50. The median age ranges from 55 to 75 years, but there has been a record of younger sufferers of the disease. It affects men more than women, but some studies have reported equal prevalence in both sexes. There is improved overall survival when an adjuvant therapy is combined with surgery in the treatment of cholangiocarcinoma.

Gallstones are the commonest benign cause of obstructive jaundice. The stones get impacted in the lumen of the CBD causing intraluminal obstruction to the flow of bile into the duodenum. Cholelithiasis develops in about 10%–20% of patients with gallbladder stones worldwide. Screening ultrasound combined with magnetic resonance cholangiopancreatography (MRCP) adequately confirms the presence of CBD stones. Open or laparoscopic cholecystectomy and CBD exploration for the retrieval of stones are the treatments of choice. The retrieval of stones can also be achieved via endoscopic retrograde cholangiopancreatography. Duodenal tumours are considered rare tumours in the gastrointestinal (GI) tract and represent less than 1% of all GI tumors. They present as obstructive jaundice when the ampulla of Vater is infiltrated by the tumour. Diagnosis is confirmed by gastro-duodenoscopy where the tumour may be visualised and biopsied, followed by a CT scan to stage and also determine resectability. Pancreatocoduodenectomy is the treatment of choice followed by adjuvant chemotherapy.

In the Korle-Bu Teaching Hospital, comprehensive data on the causes and socio-demographic characteristics of patients with obstructive jaundice are lacking. The current study therefore aimed to analyse the age at presentation, sex distribution, and the aetiology of patients who presented with obstructive jaundice to the hospital over a 3-year period.

Materials and Methods

This was a hospital-based retrospective study of all cases of obstructive jaundice that were seen over a 36-month period from May 2017 to April 2020, at the Hepatobiliary Unit of the Korle-Bu Teaching Hospital in Accra, Ghana. The unit serves as a referral centre for cases of obstructive jaundice from across Ghana. The diagnosis of obstructive jaundice was based on the presence of predominantly direct hyperbilirubinaemia and a dilated biliary system on imaging (ultrasound, CT scan, MRI, or MRCP). All images were reviewed again at a multidisciplinary meeting led by the radiology department, in order to confirm or rule out other differential diagnosis responsible for biliary obstruction such as sclerosing cholangitis, primary biliary cirrhosis, and physiological or drug-induced cholestasis. Cases with incomplete data were excluded from the analysis. The demographic data and diagnosis of all cases of obstructive jaundice seen over the study period were retrieved from the outpatient and in-patient records. Data were entered into Microsoft Excel 2013 and cleaned. Frequencies and percentages were run for aetiologies of obstructive jaundice. Mean ages and sex ratios were calculated. Categorical variables were compared using Chi-square test and numerical variables compared using the Student t-test. Differences were considered significant if P < 0.05.

The study was approved by the Scientific and Technical Committee of the Korle-Bu Teaching Hospital (ID number: STC 00079/2020).

Results

Three hundred and sixty cases of obstructive jaundice were retrieved from the records. There were 141 males (39.2%) and 219 females (60.8%), giving a male-to-female ratio of 1:1.6. The mean age of the patients was 56.8 (SD, 15.9) years. Malignant causes of obstructive jaundice were seen in 314 (87.2%) and benign causes in 46 (12.8%) [Table 1]. The mean age of patients with benign causes (40.4 [SD, 15.7] years) was significantly lower than that of malignant causes (59.4 [SD, 14.9] years) (P < 0.0001). Eighteen (39.1%) of the patients with benign conditions were males, whilst 123 (39.2%) of those with malignant conditions were males. There was no significant difference in the sex ratios between those with benign and those with malignant conditions (P = 0.996).

The commonest cause of obstructive jaundice was tumour of the head of pancreas 139 (38.61%), followed by gallbladder tumour 81 (22.5%), cholangiocarcinoma 43 (11.94%), and periampullary tumour 27 (7.50%). The commonest benign cause was gallstones followed by benign common bile strictures. None of those with strictures had any past history of biliary surgery or instrumentation.

Another group classified as “others” in our results contributed to 6.67% of the causes of obstructive jaundice. These included malignancies such as retroperitoneal tumours infiltrating the periampullary region, and secondary metastasis to the porta hepatis lymph nodes from colon, breast, and gastric tumours, 9 (2.50%). The benign conditions that contributed to “others” were drug-induced cholestasis, autoimmune hepatitis, and choledochal cyst, 15(4.17%), which presented to the surgical department for further evaluation.

Discussion

The results of the study showed a female preponderance of obstructive jaundice of 60.8%. This is at variance with some studies done previously in Nigeria where more males presented...
Obstructive jaundice in our setting was more prevalent in females. Malignant aetiologies were more common than benign ones: pancreatic head and gallbladder cancers were the commonest malignancies, whilst choledocholithiasis was the commonest benign cause. Malignant causes occurred in older patients than benign conditions, but there was no difference in sex ratios between the two categories.

Clinicians should have a high index of suspicion for malignancy in the evaluation of obstructive jaundice even if the age of presentation is less than what is typically reported in the literature. This will ensure early diagnosis and offer an opportunity for surgical resection, which offers the best prospect towards a long-term survival.

This study had some limitations. The data may not be truly representative of the national situation of obstructive jaundice, as our institution is a referral centre and so is likely to receive only complex cases of obstructive jaundice. The noninclusion of histopathology in the analysis may affect the reliability of some of the diagnoses. The study findings, however, provide some baseline information for further studies on the pattern and epidemiology of obstructive jaundice in Ghana.

**Conclusion**

Obstructive jaundice in our setting was more prevalent in females. Malignant aetiologies were more common than benign ones: pancreatic head and gallbladder cancers were the commonest malignancies, whilst choledocholithiasis was the commonest benign cause. Malignant causes occurred in older patients than benign conditions, but there was no difference in sex ratios between the two categories.

**Acknowledgement**

We thank the entire staff of the Hepatobiliary Unit for their contributions in the management of these patients and to Prof. E. Q. Archampong, Prof. J. C. B. Dakubo, and Prof. Alfred Yawson for proof-reading and corrections.

**Authors’ contribution**

OKA conceived the idea, designed and wrote the article. CN and DO undertook data collection and contributed to the writing of the article. FO, AAYA, BDS, KT, AAN, and TA reviewed the article and contributed to the writing of the final article.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

---

**Table 1: Aetiology of obstructive jaundice**

| Aetiology               | Number of cases, N (%) |
|-------------------------|------------------------|
| Malignant causes        |                        |
| Tumour of head of pancreas | 139 (38.61)           |
| Gallbladder tumour      | 81 (22.50)             |
| Cholangiocarcinoma      | 43 (11.94)             |
| Periampullary tumour    | 27 (7.50)              |
| Duodenal tumour         | 15 (4.17)              |
| Others                  | 9 (2.50)               |
| Benign causes           |                        |
| Gallstones              | 23 (6.39)              |
| Benign CBD strictures   | 8 (2.22)               |
| Others                  | 15 (4.17)              |
| Total                   | 360 (100)              |
References

1. Cameron AM. Obstructive Jaundice - An Overview | ScienceDirect Topics [Internet]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/obstructive-jaundice. [Last accessed on 14 May 2020].

2. Björnsson E, Gustafsson J, Borkman J, Kilander A. Fate of patients with obstructive jaundice. J Hosp Med 2008;3:117-23.

3. Illic M, Illic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016;22:9694-705.

4. Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568.

5. Boyan WP Jr, Klepner S, Farr M, Kopelan A, Paragi P, Clarke K. A month for gallbladder cancer: A case report of four gallbladder cancers over a 30-day period at a community hospital. World J Oncol 2015;6:495-8.

6. Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: Epidemiology and genetic risk associations. Chin Clin Oncol 2019;8:31.

7. Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder cancer in the 21st century. J Oncol 2015;2015:967472.

8. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010;15:168-81.

9. Tischoff I, Tannapfel A. [Hepatocellular carcinoma and cholangiocarcinoma—Different prognosis, pathogenesis and therapy]. Zentralbl Chir 2007;132:300-5.

10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84.

11. Gupta AK, Singh A, Goel S, Tank R. Profile and pattern of obstructive jaundice cases from a tertiary care teaching hospital of Uttar Pradesh. Int Surg J 2017;4:743-6.

12. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al.; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 2012;61:1657-69.

13. Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40.

14. Molvar C, Glaenzer B. Choledocholithiasis: Evaluation, treatment, and outcomes. Semin Intervent Radiol 2016;33:268-76.

15. Freitas ML, Bell RL, Duffy AJ. Choledocholithiasis: Evolving standards for diagnosis and management. World J Gastroenterol 2006;12:3162-7.

16. Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: Advances in diagnosis and surgical management. World J Gastrointest Surg 2016;8:212-21.

17. Velandia C, Morales RD, Coello C, Mendoza AG, Pérez G, Aguero E. Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. Eancancermedicalscience 2018;12:816.

18. Lawal D, Oluwole S, Makanjuola D, Adekunle M. Diagnosis, management and prognosis of obstructive jaundice in Ile-Ife, Nigeria. West Afr J Med 1998;17:255-60.

19. Rahman GA, Yusuf IF, Faniyi AO, Etonyeaku AC. Management of patients with obstructive jaundice: Experience in a developing country. Nig Q J Hosp Med 2011;21:75-9.

20. Chalya PL, Kanumba ES, McMheme M. Etiological spectrum and treatment outcome of obstructive jaundice at a University Teaching Hospital in Northwestern Tanzania: A diagnostic and therapeutic challenges. BMC Res Notes 2011;4:147.

21. Sha I, Dong Y, Niu H. A prospective study of risk factors for in-hospital mortality in patients with malignant obstructive jaundice undergoing percutaneous biliary drainage. Medicine (Baltimore) 2019;98:e15131.

22. La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, et al. Adjusting Ca19-9 values to predict malignancy in obstructive jaundice: Influence of bilirubin and C-reactive protein. World J Gastroenterol 2012;18:4150-5.

23. Darko R, Archampong EQ. The changing pattern of cholelithiasis in Accra. West Afr J Med 1994;13:204-8.

24. Siddique K, Ali Q, Mirza S, Jamil A, Ehsan A, Latif S, et al. Evaluation of the aetiological spectrum of obstructive jaundice. J Ayub Med Coll Abbottabad 2008;20:62-6.